Trials / Completed
CompletedNCT03902613
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- New York State Psychiatric Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, the project focuses on the importance of dopamine signaling in the process. Participants will have two different brain scans (MRI and PET scan). They will also have treatment for your depression with an FDA approved medication, lurasidone (Latuda). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone | Participant will have an open label trial of lurasidone for eight weeks. |
Timeline
- Start date
- 2019-02-07
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2019-04-04
- Last updated
- 2023-11-13
- Results posted
- 2020-10-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03902613. Inclusion in this directory is not an endorsement.